Article Text

Download PDFPDF
Exenterations 60 Years After First Description: Results of a Survey Among US and German Gynecologic Oncology Centers
  1. Simone Marnitz, MD*,
  2. Sean Dowdy, MD,
  3. Malgorzata Lanowska, MD,
  4. Achim Schneider, MD, MPH,
  5. Karl Podratz, MD and
  6. Christhardt Köhler, MD
  1. *Department of Radiooncology, Charité Universitätsmedizin Berlin, Berlin, Germany;
  2. Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN; and
  3. Department of Gynecology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  1. Address correspondence and reprint requests to Achim Schneider, MD, MPH, Department of Gynecology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, D-12200 Berlin, Germany. E-mail: achim.Schneider{at}charite.de.

Abstract

Objective: Sixty years after exenterative surgery was introduced into gynecologic oncology, the indications and contraindications, techniques, and adjuvant therapies after exenteration are controversially discussed between gynecologic oncologists.

Methods: To evaluate the current patterns of care, a questionnaire with 48 items was sent to 40 Society of Gynecologic Oncologists member clinics with fellowship programs and all 38 German teaching hospitals for gynecologic oncology.

Results: The mean number of exenterations performed during the last 5 years was comparable in both countries. Consistently, (central) recurrent cervical cancer or persistent tumor after chemoradiation is the main indication. Before exenteration, positron emission tomography-computed tomography is mostly performed in the United States, whereas magnetic resonance imaging is the preferred imaging tool in Germany. Staging is more often done surgically in the United States (61%) compared with Germany (32%). None of the US institutions recommend an exenteration for patients with International Federation of Gynecology and Obstetrics stage IVA in contrast to 43% in Germany. In the case of fistula to the bladder and/or rectum, exenteration was recommended only by 29% and 61% in US and German clinics, respectively. In Germany, interdisciplinarity with general surgeons, urologists, plastic surgeons, and radio-oncologists is more common. There is consensus to apply adjuvant therapy after exenteration in patients with positive margins and/or positive lymph nodes. However, adjuvant therapy is more frequently recommended in Germany (93%) than in the United States (74%).

Conclusions: Our data reflect considerable differences about indications and contraindications, preoperative staging, and adjuvant therapy for pelvic exenteration between Germany and the United States.

  • Pelvic exenteration
  • Indication
  • Primary cervical cancer
  • Recurrent cervical cancer
  • Palliative exenteration
  • Survey
  • Chemoradiation

Statistics from Altmetric.com

Footnotes

  • Supplemental digital content is available for this paper. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this paper on the journal's Web site (http://journals.lww.com/ijgc/Pages/Default.aspx).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.